Orencia (abatacept) ya amince da shi a ranar 23 ga watan Mayu, 2005 a matsayin sabon likita don magance alamomi da alamomin cututtuka na rheumatoid . Orencia ya shiga wasu abubuwa guda uku na DMARD a lokacin jinkirin cigaba da lalacewar tsarin, ciki har da kwayar necrosis factor antagonists (magungunan TNF):
Simponi (golimumab) da Cimzia (certolizumab pegol), da wasu masu safarar TNF guda biyu, an amince da su daga baya.
Orencia an yarda dashi ga masu fama da cututtuka marasa lafiya wadanda ke da rashin dacewar amsawa ga daya daga cikin kwayoyin gyaran cututtuka (DMARDs) wadanda banda masu tayar da cutar ta TNF sun haɗa da:
- Rheumatrex (methotrexate)
- Arava (leflunomide)
- Plaquenil (hydroxychloroquine)
- Azulfidine (sulfasalazine)
Yaya aka yi Adanarcia?
Hakazalika da Remicade (infliximab), an bayar da Orencia a matsayin jigilar jini (IV). An yi amfani da Orencia fiye da minti 30, ba kamar infliximab wanda aka gudanar a kimanin sa'o'i 2 ba.
Bayan an fara gudanar da mulkin, an ba Orencia a makonni 2 da hudu, to, kowane makonni hudu bayan haka. Orencia za a iya amfani dashi ne kawai (ko ɗaya) ko kuma tare da sauran DMARDs wadanda ba TNT ba ne saboda an kara yawan haɗari da haɗuwa.
A watan Yuli na 2011, FDA ta amince da tsarin da ake yi wa kansa mai inganci na Orencia.
Hanyoyin da ke da dangantaka da Orencia
Hanyoyi na ciki sun haɗa amma ba'a iyakance ga:
- rashin halayen rashin lafiyan da ba zai iya zama barazanar rai ba
- kamuwa da cuta
- matsalolin na numfashi (musamman ma marasa lafiya da cututtukan da ke fama da cutar ta jiki da kuma rashin lafiya)
Facts to Yi la'akari Kafin kokarin Orencia
Kudirin Orencia ciki har da saka idanu shi ne mafi mahimmanci fiye da masu tayar da hankulan TNF wadanda ba su da maƙwabtaka da adalimumab da ƙananan amma ba su da kasa. Orencia ya nuna kawai amintaccen amfani idan aka yi amfani da shi kadai don haka an fi dacewa da shi tare da wani DMARD kamar su hanya ko wasu don cimma sakamako mafi kyau.
Har sai an samu karin sanin kwarewa tare da Orencia, wasu likitoci sun ajiye shi ga marasa lafiya wadanda suka kasa akalla biyu daga cikin mahalarta TNF guda uku (wanda aka auna ta hanyar tasiri ko rashin amfani). Wadannan magungunan maganin arthritis sun kasance a kasuwar tun lokacin da aka gabatar da kararraki a 1999 kuma sun nuna rawar da za su kasance mai hadarin gaske.
Orencia vs. Anakinra
Anakinra ba zai yi amfani da shi ba don magance cututtuka na rheumatoid saboda bukatar da ake yi a yau da kullum da kuma amfani mai iyaka idan aka kwatanta da masu tayar da hankulan TNF wanda ke toshe ayyukan TNF (cytokine ko manzo tsakanin kwayoyin halitta). TNF wani fili ne da ke da muhimmiyar rawa wajen haifar da kumburi da lalacewa a arthritis na rheumatoid.
Kwayoyin T suna taka muhimmiyar rawa wajen haifar da alamomi da alamun cututtuka na cututtuka na rheumatoid. Orencia yana ƙaddamar da sigina a cikin jini wanda ya wajaba ga ƙwayoyin T don yin lalacewar su.
Kineret (anakinra) ya kaddamar da kwayar cytokine IL-1 wanda ke taka rawar da zai lalata kasusuwan da ke cikin ɓarkewar cutar.
Amsar da Scott J. Zashin, MD, ya bayar, shine masanin farfesa a Jami'ar Texas, na Makarantar Kimiyya, a Jami'ar Texas, a Dallas, Texas. Dokta Zashin kuma likitan likitanci a asibitin Presbyterian na Dallas da Plano. Ya kasance abokin tarayya na Cibiyar Kwalejin Kwararrun Amirka da Kwararrun Rheumatology na Amurka da kuma memba na Ƙungiyar Magunguna ta Amirka.